The Cancer and Cardiovascular Research Building was added to the Biomedical Discovery District in 2013.
It is part of the University of Minnesota in Minneapolis and is a modern $200 million, 280,000ft², building which houses over a thousand scientists and researchers in its state-of-the-art laboratories.
The Cancer and Cardiovascular Research Building consists of three departments: the Lillehei Heart Institute, the Department of Integrative Biology and Physiology, and the Masonic Cancer Center.
Lillehei Heart Institute and the Department of Integrative Biology and Physiology
The scientists and researchers working at the Lillehei Heart Institute and the Department of Integrative Biology and Physiology focus on cardiac regeneration, cardiac development, muscular dystrophy, congenital heart medicine, and genomics.
Cardiovascular Disease Research programs
The Lillehei Heart Institute research programs focus on cardiovascular genomics, heart development, heart regeneration, stem cell therapies, personalized medicine, heart failure, vascular biology, and device design to treat cardiovascular diseases. New research teams and ultramodern research facilities have helped increase grant funding significantly and resulted in five large programmatic grants. The extra funding facilitates collaborations and synergies to promote new therapies.
The Department of Integrative Biology and Physiology (IBP) current research is pioneering in the areas of cardiovascular/muscle, metabolism/obesity and hypertension.
The Masonic Cancer Center
The Masonic Cancer Center is the main designated facility for cancer research. It houses chemical biologists focusing on studying chemical carcinogens as a cause of cancer, and new innovative therapeutic strategies to fight cancer. It lists seven major research programs as the following: carcinogenesis and chemoprevention; cellular mechanisms; genetic mechanisms; immunology; screening, prevention, etiology, and cancer survivorship (SPECS); and transplant biology and therapy.
Cancer Prevention Research Programs
The Carcinogenesis and Chemoprevention Program research themes are tobacco and cancer; chemical and molecular mechanisms of carcinogenesis; and chemoprevention of cancer. The 27 members of the program aim to evaluate the causes, chemical and molecular mechanisms, and prevention of carcinogenesis and to develop practical methods for cancer prevention.
The Cellular Mechanisms program research themes are, Signal Transduction within and between tumor cells; Epigenetic Regulation of the Cancer Transcriptome; and Tumor Stroma Remodeling. The key aim of the programs’ members is to develop new strategies for prevention, early detection, diagnostics and prognosis, and treatment of cancer.
The Genetic Mechanisms (GM) research program has 34 members and is focusing on three specified themes: Cancer gene discovery and analysis; Genome stability; and cancer gene therapy and genome modification.
The Immunology Program is focused on four research themes, namely: Mechanisms of lymphocyte tolerance; Lymphocyte activation and signal transduction; Mechanisms of lymphocyte development and Tumor immunology and immunotherapy. The 21 Immunology program members work on developing immunotherapies that overcome the major obstacles associated with generating a durable immune response against tumor-associated antigens.
The Screening, Prevention, Etiology and Cancer Survivorship (SPECS) Program has 60 members. The SPECS research themes focus on the following: Pediatric and adult cancer epidemiology; Cancer risk reduction and Cancer diagnosis, outcomes, and survivorship. The aim of the program is to understand biological and behavioural factors in the causation or origination of cancer. SPECS ultimate scientific goal would be to reduce behaviours that may lead to cancer or enhance behaviours that decrease the risk of getting cancer.
The Transplant Biology and Therapy Research Program themes are: Hematopoietic reconstitution; immunological reconstitution; Immunological reconstitution; Relapse prevention and treatment. The 41 members strive to minimise or eliminate factors limiting hematopoietic stem cell transplantation. These include regimen-related toxicities, graft-versus-host disease (GVHD), and delayed reconstitution of immunity.
- Production Facilities Expansion, Novo Nordisk, Chartres, FranceNovo Nordisk, a global pharmaceutical leader, has set in motion an extensive expansion project for its production facility in Chartres,
- Manufacturing Pharmaceuticals In SpaceVarda Space Industries, a California-based startup, is venturing into the realm of pharmaceutical manufacturing in microgravity with the goal of
- Plasma-Derived Therapies Manufacturing Plant, 2030, Takeda, Osaka, JapanTakeda plans to invest approximately 100 Billion Yen ( 762,330,000 Million USD) to construct a new manufacturing plant for plasma-derived
- Continuous Manufacturing Line for Oral Solids, WuXi STA, ChinaWuXi STA, a subsidiary of WuXi AppTec, opened the doors of its first pharmaceutical product Continuous Manufacturing (CM) line for
- BioNTech Boosts Autonomy with In-House Plasmid DNA Manufacturing Facility in MarburgThe construction of BioNTech’s first in-house plasmid DNA processing plant in Marburg, Germany, has now been completed, the company announced
- Plasmid DNA Manufacturing Facility, Catalent, Gosselies, BelgiumThe opening of Catalent’s new ultra-modern, commercial-scale plasmid DNA (pDNA) manufacturing facility in Gosselies, Belgium was announced on the 26th